Dynavax Technologies Corp
NASDAQ:DVAX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.05
14.98
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Dynavax Technologies Corp
Dynavax Technologies Corp
Other Current Liabilities
Dynavax Technologies Corp
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dynavax Technologies Corp
NASDAQ:DVAX
|
Other Current Liabilities
$14k
|
CAGR 3-Years
-97%
|
CAGR 5-Years
-75%
|
CAGR 10-Years
-45%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Liabilities
$11.7B
|
CAGR 3-Years
197%
|
CAGR 5-Years
551%
|
CAGR 10-Years
53%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Liabilities
$357.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
36%
|
CAGR 10-Years
27%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Liabilities
$627.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
24%
|
|
Dynavax Technologies Corp
Glance View
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. The company is headquartered in Emeryville, California and currently employs 311 full-time employees. The company went IPO on 2004-02-19. The firm's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The firm also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The firm is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). The company is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.
See Also
What is Dynavax Technologies Corp's Other Current Liabilities?
Other Current Liabilities
14k
USD
Based on the financial report for Sep 30, 2024, Dynavax Technologies Corp's Other Current Liabilities amounts to 14k USD.
What is Dynavax Technologies Corp's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
-45%
The average annual Other Current Liabilities growth rates for Dynavax Technologies Corp have been -97% over the past three years , -75% over the past five years , and -45% over the past ten years .
You don't have any saved screeners yet
